Mics Centrum Medyczne Torun

The trials here

What the 18 trials at this site are about, from their registry records.

Conditions

• Acute myeloid leukaemia3 trials
• Psoriasis3 trials
• Acute lymphoblastic leukaemia2 trials
• Atopic dermatitis (eczema)2 trials
• Multiple myeloma2 trials
• Myelodysplastic syndromes2 trials
• Obesity2 trials
• Psoriatic arthritis2 trials
• Rheumatoid arthritis2 trials
• Ankylosing spondylitis1 trial
• Chronic lymphocytic leukaemia1 trial
• Endometriosis1 trial
• and 2 more

Phase

• Phase 312 trials
• Phase 12 trials
• Phase 22 trials
• Phase 1/21 trial
• Phase 41 trial

Status

• Active, not recruiting8 trials
• Completed3 trials
• Not yet recruiting2 trials
• Recruiting2 trials
• Terminated2 trials
• Withdrawn1 trial

Lead sponsor

• Ascletis Pharma (China) Co. Ltd.2 trials
• Bristol-Myers Squibb2 trials
• Ryvu Therapeutics SA2 trials
• Takeda2 trials
• Celgene Corp.1 trial
• and 9 more

Running trials

• Not yet recruiting

  A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis

  2025-525022-35-00· Phase 3· Hunan Mabgeek Biotech Co. Ltd.· Source

• Recruiting

  Efficacy and Safety of Once-Daily Oral ASC30 Compared with Placebo in Participants with Obesity or Overweight with Type 2 Diabetes Mellitus

  2026-526336-39-00· Phase 3· Ascletis Pharma (China) Co. Ltd.· Source

• Recruiting

  Efficacy and Safety of Once-Daily Oral ASC30 Compared with Placebo in Participants with Obesity or Overweight with Weight-Related Comorbidities

  2026-526172-23-00· Phase 3· Ascletis Pharma (China) Co. Ltd.· Source

• Recruiting

  Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  NCT07648264· Phase 3· CSL Behring· Source

  Contact: Trial Registration Coordinator

• Active, not recruiting

  Study of GS-0151 in Participants With Rheumatoid Arthritis

  NCT06902519· Phase 1· Gilead Sciences· Source

• Active, not recruiting

  A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

  NCT06671483· Phase 3· Takeda· Source

• Recruiting

  A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

  NCT06629779· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)

  NCT06516965· Phase 3· Incyte Corporation· Source

• Active, not recruiting

  A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

  NCT06550076· Phase 3· Takeda· Source

• Active, not recruiting

  A trial to determine the safety and effectiveness of CC-92480 in combination with bortezomib and dexamethasone as compared to pomalidomide in combination with bortezomib and dexamethasone in people who have Multiple Myeloma that is not responsive after treatment or has returned after a period of treatment.

  2023-509859-13-00· Phase 3· Celgene Corp.· Source

• Active, not recruiting

  A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate

  NCT04909801· Phase 3· Bristol-Myers Squibb· Source

• Active, not recruiting

  A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

  NCT04908189· Phase 3· Bristol-Myers Squibb· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Multiple myeloma1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Recruiting

  A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT07711418· Phase 3· Nektar Therapeutics· Source

• Terminated

  Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML

  NCT06268574· Phase 2· Ryvu Therapeutics SA· Source

• Completed

  Tofacitinib in early active axial spondyloarthritis: a prospective, randomized, double-blind, placebo-controlled multicentre study - FASTLANE

  2023-505050-18-00· Phase 4· Charite Universitaetsmedizin Berlin KöR· Source

• Completed

  A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

  NCT05560646· Phase 2· Organon and Co· Source

• Active, not recruiting

  First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

  NCT04067336· Phase 1/2· Kura Oncology, Inc.· Source

• Terminated

  RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome

  NCT04021368· Phase 1· Ryvu Therapeutics SA· Source